Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: PTSD, Alcohol Abuse, Alcoholism
Interventions: Topiramate, Placebo administration; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Influenza Infection
Interventions: VAX102 [Flagellin.HuM2e], Placebo; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Lenexa, Kansas • Galveston, Texas

Conditions: Cleft Palate
Interventions: Oral acetaminophen, Ofirmev®, Opioid only; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 5 Months to 5 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Uremic Pruritus
Interventions: PA101B, Placebo; Drug
Lead sponsor: Patara Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 13
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Northridge, California + 10 more

Conditions: System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
Interventions: Belumosudil (KD025), Placebo; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 26
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more

Conditions: Asthma
Interventions: PLACEBO, MEDI528 9 mg/kg; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Winston-Salem, North Carolina + 1 more

Conditions: Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Dexmedetomidine, Placebos; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 89 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more

Conditions: Alzheimer Disease
Interventions: BPN14770, BPN14770 placebo, Donepezil, Donepezil placebo, Scopolamine 0.6 MG/ML, Scopolamine placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Adhesive Capsulitis, Frozen Shoulder
Interventions: Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 30
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 25 more

Conditions: Ketamine Adverse Reaction, Effects of; Anesthesia, Spinal and Epidural, in Pregnancy, Complication of Labor and/or Delivery
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Neuropathies
Interventions: TAK-128, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 40
States / cities: Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 37 more

Conditions: Becker Muscular Dystrophy
Interventions: Sodium Nitrate, Sodium Nitrate - double dose, Placebo, Increased exercise intensity; Dietary Supplement · Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 15 Years to 45 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Peanut Allergy
Interventions: Peanut flour OIT; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Knee Discomfort, Pain Physical Activity
Interventions: Polyherbal capsule, Placebo capsule; Dietary Supplement
Lead sponsor: NewChapter, Inc.; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Homestead, Florida • Duncansville, Pennsylvania • Dallas, Texas + 2 more

Conditions: Dry Mouth, Xerostomia, OSA, Sleep Apnea
Interventions: Test Oral Spray, Placebo Oral Spray; Device
Lead sponsor: You First Services; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Coronary Syndrome (ACS)
Interventions: cangrelor, Placebo; Drug · Other
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions: VERVE-102, Placebo; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DeSoto, Texas

Conditions: Breast Carcinoma, Kidney Carcinoma, Carcinoma
Interventions: Functional Near-Infrared Spectroscopy, Questionnaire Administration, Virtual Technology Intervention, Cold Stimulation; Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Postoperative Complications, Cataract
Interventions: Bromfenac, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 39
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 34 more

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: mavacamten, Placebo; Drug
Lead sponsor: MyoKardia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aprepitant, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Covid19
Interventions: F-652, Placebo; Biological
Lead sponsor: EVIVE Biotechnology; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypertension
Interventions: olmesartan medoxomil, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more

Conditions: Smoking, Nicotine Dependence, Mental Disorders
Interventions: Cognitive / Motivational Individual Sessions, Attention Control Individual Sessions, Nicotine Patch, Group Curriculum; Behavioral · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

Treatment of Uremic Pruritus With PA101B

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)

Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy

Oral Peanut Immunotherapy

Polyherbal Capsule Formulation for Joint Health

"Hyaluronan" Formulation for Dry Mouth in Sleep Apnea Patients

Maintenance of Platelet Inhibition With Cangrelor

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Differentiating the Effects of Substance P and Beta-endorphin

Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Helping Those With Mental Illness Quit Smoking